Research programme: peptides - Enteris BioPharma/KeyBioScience
Latest Information Update: 08 Jan 2020
At a glance
- Originator Enteris BioPharma; KeyBioScience
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Obesity in USA (PO)
- 04 Nov 2017 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA (PO)
- 30 Sep 2013 Early research in Obesity in USA (PO)